Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data

EUROCARE-4 Working Group; Arduino Verdecchia; Silvia Francisci; Hermann Brenner; Gemma Gatta; Andrea Micheli; Lucia Mangone; Ian Kunkler

doi:10.1016/S1470-2045(07)70246-2

Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data

EUROCARE-4 Working Group, Arduino Verdecchia, Silvia Francisci, Hermann Brenner, Gemma Gatta, Andrea Micheli, Lucia Mangone, Ian Kunkler

Deanery of Molecular, Genetic and Population Health Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Traditional cancer-survival analyses provide data on cancer management at the beginning of a study period, and are often not relevant to current practice because they refer to survival of patients treated with older regimens that might no longer be used. Therefore, shortening the delay in providing survival estimates is desirable. Period analysis can estimate cancer survival by the use of recent data. We aimed to apply the period-analysis method to data that were collected by European cancer registries to estimate recent survival by country and cancer site, and to assess survival changes in Europe. We also compared our findings with data on cancer survival in the USA from the US SEER (Surveillance, Epidemiology, and End Results) programme.

Original language	English
Pages (from-to)	784-96
Number of pages	13
Journal	The Lancet Oncology
Volume	8
Issue number	9
DOIs	https://doi.org/10.1016/S1470-2045(07)70246-2
Publication status	Published - Sep 2007

Keywords

Age of Onset
Europe
Health Surveys
Humans
Neoplasms
Registries
SEER Program
Survival Analysis

Access to Document

10.1016/S1470-2045(07)70246-2

Cite this

@article{10d14d39c802408b8c85c6a4cd5af5c4,

title = "Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data",

abstract = "Traditional cancer-survival analyses provide data on cancer management at the beginning of a study period, and are often not relevant to current practice because they refer to survival of patients treated with older regimens that might no longer be used. Therefore, shortening the delay in providing survival estimates is desirable. Period analysis can estimate cancer survival by the use of recent data. We aimed to apply the period-analysis method to data that were collected by European cancer registries to estimate recent survival by country and cancer site, and to assess survival changes in Europe. We also compared our findings with data on cancer survival in the USA from the US SEER (Surveillance, Epidemiology, and End Results) programme.",

keywords = "Age of Onset, Europe, Health Surveys, Humans, Neoplasms, Registries, SEER Program, Survival Analysis",

author = "{EUROCARE-4 Working Group} and Arduino Verdecchia and Silvia Francisci and Hermann Brenner and Gemma Gatta and Andrea Micheli and Lucia Mangone and Ian Kunkler",

year = "2007",

month = sep,

doi = "10.1016/S1470-2045(07)70246-2",

language = "English",

volume = "8",

pages = "784--96",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "9",

}

TY - JOUR

T1 - Recent cancer survival in Europe

T2 - a 2000-02 period analysis of EUROCARE-4 data

AU - EUROCARE-4 Working Group

AU - Verdecchia, Arduino

AU - Francisci, Silvia

AU - Brenner, Hermann

AU - Gatta, Gemma

AU - Micheli, Andrea

AU - Mangone, Lucia

AU - Kunkler, Ian

PY - 2007/9

Y1 - 2007/9

N2 - Traditional cancer-survival analyses provide data on cancer management at the beginning of a study period, and are often not relevant to current practice because they refer to survival of patients treated with older regimens that might no longer be used. Therefore, shortening the delay in providing survival estimates is desirable. Period analysis can estimate cancer survival by the use of recent data. We aimed to apply the period-analysis method to data that were collected by European cancer registries to estimate recent survival by country and cancer site, and to assess survival changes in Europe. We also compared our findings with data on cancer survival in the USA from the US SEER (Surveillance, Epidemiology, and End Results) programme.

AB - Traditional cancer-survival analyses provide data on cancer management at the beginning of a study period, and are often not relevant to current practice because they refer to survival of patients treated with older regimens that might no longer be used. Therefore, shortening the delay in providing survival estimates is desirable. Period analysis can estimate cancer survival by the use of recent data. We aimed to apply the period-analysis method to data that were collected by European cancer registries to estimate recent survival by country and cancer site, and to assess survival changes in Europe. We also compared our findings with data on cancer survival in the USA from the US SEER (Surveillance, Epidemiology, and End Results) programme.

KW - Age of Onset

KW - Europe

KW - Health Surveys

KW - Humans

KW - Neoplasms

KW - Registries

KW - SEER Program

KW - Survival Analysis

U2 - 10.1016/S1470-2045(07)70246-2

DO - 10.1016/S1470-2045(07)70246-2

M3 - Article

C2 - 17714993

VL - 8

SP - 784

EP - 796

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 9

ER -

Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data

Abstract

Keywords

Access to Document

Fingerprint

Cite this